Published in J Pharmacol on April 17, 1986
Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation. J Clin Invest (1989) 1.15
Comparative protective effects of nicardipine, flunarizine, lidoflazine and nimodipine against ischaemic injury in the hippocampus of the Mongolian gerbil. Br J Pharmacol (1988) 1.13
Direct activation of Ca2+ channels by palmitoyl carnitine, a putative endogenous ligand. Br J Pharmacol (1987) 1.09
Drugs acting on calcium channels: potential treatment for ischaemic stroke. Br J Clin Pharmacol (1992) 1.02
Inhibition of cholesteryl ester deposition in macrophages by calcium entry blockers: an effect dissociable from calcium entry blockade. Br J Pharmacol (1987) 0.99
Interaction of palmitoyl carnitine with calcium antagonists in myocytes. Br J Pharmacol (1989) 0.95
Interaction of phorbol esters with Ca2+ channels in smooth muscle. Br J Pharmacol (1987) 0.86
Effects of calcium channel antagonists and facilitators on beating of primary cultures of embryonic chick heart cells. Br J Pharmacol (1988) 0.85
The effects of calcium antagonists on calcium overload contractures in embryonic chick myocytes induced by ouabain and veratrine. Br J Pharmacol (1989) 0.84
Pharmacological analysis of the effects of Bay K 8644 and organic calcium antagonists on the mouse isolated distal colon. Br J Pharmacol (1988) 0.83
Selective antagonism of calcium channel activators by fluspirilene. Br J Pharmacol (1990) 0.81
Bay K 8644 induced necrosis in murine skeletal muscle in vitro: myofibre breakdown precedes significant alterations of intracellular [Ca] or pH. Acta Neuropathol (1989) 0.79
Identification of a novel calcium antagonist binding site in rat brain by SR 33557. Br J Pharmacol (1993) 0.78
Effects of Compounds Affecting Calcium Channels on Phytochrome- and Blue Pigment-Mediated Pulvinar Movements of Cassia fasciculata. Plant Physiol (1989) 0.78
Comparison of the cardiovascular effects of trans-diclofurime with different types of calcium antagonists in conscious spontaneously hypertensive rats. Br J Pharmacol (1988) 0.77
Reduction by lifarizine of the neuronal damage induced by cerebral ischaemia in rodents. Br J Pharmacol (1995) 0.77
Effects of calcium channel blockers on gastric emptying and acid secretion of the rat in vivo. Br J Pharmacol (1986) 0.77
Proceedings of the British Pharmacological Society. 10th-18th September 1986. Abstracts. Br J Pharmacol (1986) 0.75
Different insulin-secretory responses to calcium-channel blockers in islets of lean and obese (ob/ob) mice. Biochem J (1988) 0.75
X. International Union of Pharmacology recommendations for nomenclature of new receptor subtypes. Pharmacol Rev (1996) 13.17
Assessment of "Ca2+ -antagonist" effects of drugs in K+ -depolarized smooth muscle. Differentiation of antagonist subgroups. Naunyn Schmiedebergs Arch Pharmacol (1982) 1.84
Antagonism of adenosine 5'-triphosphate-induced relaxation by 2-2'-pyridylisatogen in the taenia of guinea-pig caecum. Br J Pharmacol (1975) 1.68
A functional correlate for the dihydropyridine binding site in rat brain. Nature (1985) 1.68
Interactions between a "calcium channel agonist", Bay K 8644, and calcium antagonists differentiate calcium antagonist subgroups in K+-depolarized smooth muscle. Naunyn Schmiedebergs Arch Pharmacol (1984) 1.24
Alpha 2-adrenoceptor subtypes and imidazoline-like binding sites in the rat brain. Br J Pharmacol (1990) 1.23
Identification of separate receptors for adenosine and adenosine 5'-triphosphate in causing relaxations of the isolated taenia of the guinea-pig caecum. Br J Pharmacol (1976) 1.22
Proceedings: 2-2' pyridylisatogen tosylate: an antagonist of the inhibitory effects of ATP on smooth muscle. Br J Pharmacol (1974) 1.15
Direct inhibitory effects of some 'calcium-antagonists' and trifluoperazine on the contractile proteins in smooth muscle. Br J Pharmacol (1983) 1.14
Changing surface charge with salicylate differentiates between subgroups of calcium-antagonists. Br J Pharmacol (1984) 1.09
The mechanism of the relaxant effect of 2-2'-pyridylisatogen on the isolated taenia of the guinea-pig caecum. Br J Pharmacol (1978) 1.06
BDNF increases rat brain mitochondrial respiratory coupling at complex I, but not complex II. Eur J Neurosci (2004) 1.05
The influence of the initial stretch and the agonist-induced tone on the effect of basal and stimulated release of EDRF. Br J Pharmacol (1990) 1.03
Calcium channel activation does not increase release of endothelial-derived relaxant factors (EDRF) in rat aorta although tonic release of EDRF may modulate calcium channel activity in smooth muscle. J Cardiovasc Pharmacol (1987) 1.01
The presence of -adrenoceptors in the guinea-pig seminal vesicle. Br J Pharmacol (1972) 1.00
(8a alpha,12a alpha,13a alpha)-5,8,8a,9,10,11,12,12a,13,13a-decahydro- 3-methoxy-12-(methylsulfonyl)-6H-isoquino[2,1-g][1,6]naphthyridi ne, a potent and highly selective alpha 2-adrenoceptor antagonist. J Med Chem (1989) 0.98
Differences between the effects of calcium antagonists in the pithed rat preparation. J Cardiovasc Pharmacol (1983) 0.97
Emotional memory impairments in a genetic rat model of depression: involvement of 5-HT/MEK/Arc signaling in restoration. Mol Psychiatry (2011) 0.97
[3H]-idazoxan binds with high affinity to two sites on hamster adipocytes: an alpha 2-adrenoceptor and a non-adrenoceptor site. Br J Pharmacol (1989) 0.96
Changes in EEG spectral power in the prefrontal cortex of conscious rats elicited by drugs interacting with dopaminergic and noradrenergic transmission. Br J Pharmacol (1999) 0.96
Changes in mitochondrial function are pivotal in neurodegenerative and psychiatric disorders: how important is BDNF? Br J Pharmacol (2014) 0.96
Alpha 2-adrenoceptors: more subtypes but fewer functional differences. Trends Pharmacol Sci (1994) 0.96
Interaction of palmitoyl carnitine with calcium antagonists in myocytes. Br J Pharmacol (1989) 0.95
Heterogeneity of alpha 2-adrenoceptors in rat cortex but not human platelets can be defined by 8-OH-DPAT, RU 24969 and methysergide. Br J Pharmacol (1990) 0.95
Characterisation of cyclooxygenase 1 and 2 expression in mouse resident peritoneal macrophages in vitro; interactions of non steroidal anti-inflammatory drugs with COX2. Biochim Biophys Acta (1995) 0.95
Vasodilation by medroxalol mediated by beta 2-adrenergic receptor stimulation. J Cardiovasc Pharmacol (1983) 0.95
"Calcium antagonists": a class of drugs with a bright future. Part II. Determination of basic pharmacological properties. Life Sci (1984) 0.95
Modulation of alpha 1-adrenoceptors in rat left ventricle by ischaemia and acyl carnitines: protection by ranolazine. J Cardiovasc Pharmacol (1993) 0.94
Competitive interactions between Bay K 8644 and nifedipine in K+ depolarized smooth muscle: a passive role for Ca2+? Naunyn Schmiedebergs Arch Pharmacol (1985) 0.94
The effect of lifarizine (RS-87476), a novel sodium and calcium channel modulator, on ischaemic dopamine depletion in the corpus striatum of the gerbil. Br J Pharmacol (1993) 0.92
Mitochondria as target for antiischemic drugs. Adv Drug Deliv Rev (2001) 0.92
Anatagonism of the inhibitory effects of adenosine 5'-triphosphate on the isolated taenia of the guinea-pig caecum: structure-activity relationships within a series of isatogen derivatives. Br J Pharmacol (1978) 0.91
Structure-affinity relationships of 12-sulfonyl derivatives of 5,8,8a,9,10,11,12,12a,13,13a-decahydro-6H-isoquino[2,1-g][1 ,6] naphthyridines at alpha-adrenoceptors. J Med Chem (1991) 0.90
Calcium antagonist properties of diclofurime isomers. II. Molecular aspects: allosteric interactions with dihydropyridine recognition sites. J Cardiovasc Pharmacol (1987) 0.90
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. J Pharmacol Exp Ther (1998) 0.90
The low-frequency blood oxygenation level-dependent functional connectivity signature of the hippocampal-prefrontal network in the rat brain. Neuroscience (2012) 0.90
[3H]-RS-15385-197, a selective and high affinity radioligand for alpha 2-adrenoceptors: implications for receptor classification. Br J Pharmacol (1992) 0.90
"Calcium antagonists": a class of drugs with a bright future. Part I. Cellular calcium homeostasis and calcium as a coupling messenger. Life Sci (1983) 0.89
GAP-43 is essential for the neurotrophic effects of BDNF and positive AMPA receptor modulator S18986. Cell Death Differ (2009) 0.89
Protective effects of ranolazine in guinea-pig hearts during low-flow ischaemia and their association with increases in active pyruvate dehydrogenase. Br J Pharmacol (1993) 0.88
Potentiation by 2,2'-pyridylisatogen tosylate of ATP-responses at a recombinant P2Y1 purinoceptor. Br J Pharmacol (1996) 0.88
The problems associated with the use of 2,2'-pyridylisatogen tosylate in evaluating the allegedly purinergic innervation of peripheral organs. J Pharm Pharmacol (1978) 0.88
Antagonism of Ca2+-induced contractions of K+-depolarized smooth muscle by local anaesthetics. Eur J Pharmacol (1985) 0.88
Inhibition of the constitutive activity of human 5-HT1A receptors by the inverse agonist, spiperone but not the neutral antagonist, WAY 100,635. Br J Pharmacol (1997) 0.87
[3H]p-aminoclonidine and [3H]idazoxan label different populations of imidazoline sites on rat kidney. Eur J Pharmacol (1993) 0.87
The neuroprotective activity of 8-alkylamino-1,4-benzoxazine antioxidants. Eur J Pharmacol (2001) 0.86
Interaction of phorbol esters with Ca2+ channels in smooth muscle. Br J Pharmacol (1987) 0.86
S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties. J Pharmacol Exp Ther (1997) 0.86
RS-45041-190: a selective, high-affinity ligand for I2 imidazoline receptors. Br J Pharmacol (1995) 0.86
Contrasting EEG profiles elicited by antipsychotic agents in the prefrontal cortex of the conscious rat: antagonism of the effects of clozapine by modafinil. Br J Pharmacol (1999) 0.86
Functional interactions of calcium-antagonists in K+-depolarized smooth muscle. Br J Pharmacol (1983) 0.84
Modulation of central noradrenergic function by RS-15385-197. Br J Pharmacol (1993) 0.84
Stereospecific blockade of alpha 2-adrenoceptors by (+)-butaclamol: implications for the characterization of dopamine receptors. J Pharm Pharmacol (1982) 0.84
The effects of calcium antagonists on calcium overload contractures in embryonic chick myocytes induced by ouabain and veratrine. Br J Pharmacol (1989) 0.84
Calcium antagonist properties of diclofurime isomers. I. Functional aspects. J Cardiovasc Pharmacol (1987) 0.84
Inhibition of peripheral sympathetic function by alpha-monofluoromethyldopa, an irreversible inhibitor of aromatic amino acid decarboxylase [proceedings]. Br J Pharmacol (1979) 0.83
Sodium modulation of 3H-agonist and 3H-antagonist binding to alpha 2-adrenoceptor subtypes. Br J Pharmacol (1993) 0.82
2-2'-Pyridylisatogen, a selective allosteric modulator of P2 receptors, is a spin trapping agent. Biochem Biophys Res Commun (1998) 0.81
Selective antagonism of calcium channel activators by fluspirilene. Br J Pharmacol (1990) 0.81
Neuroprotective effects of modulators of P2 receptors in primary culture of CNS neurones. Neuropharmacology (1999) 0.81
The effects of 2-2'-pyridylisatogen tosylate on the electrical activity of smooth muscle of the isolated taenia caeci of the guinea-pig [proceedings]. Br J Pharmacol (1978) 0.81
Regulation of AMPA receptor surface trafficking and synaptic plasticity by a cognitive enhancer and antidepressant molecule. Mol Psychiatry (2012) 0.81
Differential effects of non-peptidic tachykinin receptor antagonists on Ca2+ channels. Eur J Pharmacol (1994) 0.80
Neuroprotective properties of tianeptine: interactions with cytokines. Neuropharmacology (2003) 0.80
Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J Pharmacol Exp Ther (1995) 0.79
A one-step synthesis of 2-(2-Pyridyl)-3H-indol-3-one N-oxide: is it an efficient spin trap for hydroxyl radical? J Org Chem (2000) 0.79
Tianeptine and its enantiomers: effects on spatial memory in rats with medial septum lesions. Neuropharmacology (2001) 0.79
S 14506: novel receptor coupling at 5-HT(1A) receptors. Neuropharmacology (2001) 0.79
Modulation of sexual behaviour in the rat by a potent and selective alpha 2-adrenoceptor antagonist, delequamine (RS-15385-197). Br J Pharmacol (1996) 0.79
Atypical in vitro and in vivo binding of [3H]S-14506 to brain 5-HT1A receptors. J Neural Transm (Vienna) (1997) 0.78
Neuroprotective properties of lifarizine compared with those of other agents in a mouse model of focal cerebral ischaemia. Br J Pharmacol (1995) 0.78
Pertussis toxin-sensitive G-protein activation does not influence the response to Bay K 8644 in embryonic chick myocytes. J Cardiovasc Pharmacol (1990) 0.78
S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride. J Pharmacol Exp Ther (1998) 0.78
Identification of a novel calcium antagonist binding site in rat brain by SR 33557. Br J Pharmacol (1993) 0.78
Cerebral ischaemia reduces the density of 5-HT2 binding sites in the frontal cortex of the gerbil. Neuropharmacology (1988) 0.77
Depression of sympathetic nervous function by DL-alpha-monofluoromethyldopa, an enzyme-activated, irreversible inhibitor of L-aromatic amino acid decarboxylase. J Cardiovasc Pharmacol (1980) 0.77
Differential effects of calcium channel antagonists on histamine and pentagastrin-stimulated gastric acid secretion in the rat. Agents Actions (1985) 0.77
MDL 72567, a dihydropyridine calcium-antagonist, that causes vasodilation and direct sinus bradycardia. J Cardiovasc Pharmacol (1987) 0.77
Mitochondrial pharmacology: energy, injury and beyond. Br J Pharmacol (2014) 0.76
The alpha 2-adrenoceptor antagonist SK&F 104078 has high affinity for 5-HT1A and 5-HT2 receptors. Eur J Pharmacol (1989) 0.76
Effects of EGIS-7229 (S 21407), a novel class III antiarrhythmic drug, on myocardial refractoriness to electrical stimulation in vivo and in vitro. J Cardiovasc Pharmacol (2001) 0.76
Effects of metoclopramide and isoprenaline in the rat vas deferens; interactions with alpha-adrenoceptors. Br J Pharmacol (1980) 0.75
A modified guinea-pig stomach preparation [proceedings]. Br J Pharmacol (1977) 0.75
S 14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats. Eur J Pharmacol (1994) 0.75
Receptor classification and nomenclature: the revolution and the resolution. Trends Pharmacol Sci (1994) 0.75
The guinea-pig ileum preparation as a model for 5-HT1A receptors: anomalous effects with RS-30199-193. Br J Pharmacol (1991) 0.75
Changes in [3H]-PK 11195 and [3H]-8-OH-DPAT binding following forebrain ischaemia in the gerbil. Br J Pharmacol (1993) 0.75
Neural control of dieting. Nature (1996) 0.75
Interactions of palmitoyl carnitine with the endothelium in rat aorta. Br J Pharmacol (1990) 0.75
Quantitative analysis of the dihydropyridines, 3-(2-furoyl)-5-methoxycarbonyl-2,6-dimethyl-4-(2-nitrophenyl)- 1,4-dihydropyridine and nifedipine, by high-performance liquid chromatography with electrochemical detection. J Chromatogr (1986) 0.75
IUPHAR guidelines for classification of new receptor-subtypes. Int J Clin Pharmacol Ther (1995) 0.75
Comparison between the effects of MDL 72567 and nifedipine on various cardiovascular parameters in conscious sinoaortic-denervated rats and sham-operated controls. J Cardiovasc Pharmacol (1987) 0.75
1,9-Alkano-bridged 2,3,4,5-tetrahydro-1H-3-benzazepines with affinity for the alpha 2-adrenoceptor and the 5-HT1A receptor. J Med Chem (1990) 0.75
Nomenclature of calcium channels and channel modulators: IUPHAR classification. J Cardiovasc Pharmacol (1993) 0.75
Clozapine inhibits serotoninergic transmission by an action at alpha 1-adrenoceptors not at 5-HT1A receptors. Eur J Pharmacol (1994) 0.75
International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. Pharmacol Rev (1994) 0.75
Acylation differentiates two forms of agonist binding to rat 5-HT1A receptors. Palmitoylated G protein--agonist states? Ann N Y Acad Sci (1997) 0.75
Paired vasa deferentia: a method of reducing variability in the response to drugs. Arch Int Pharmacodyn Ther (1974) 0.75